Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8733649 | Critical Reviews in Oncology/Hematology | 2018 | 9 Pages |
Abstract
Our study indicates that FOLFOXâ¯+â¯panitumumab has the major probability to provide an improvement of survival with a good safety profile in patients with RAS WT mCRC with an added value from selection based on sidedness.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Domenico Ciliberto, Nicoletta Staropoli, Francesca Caglioti, Silvia Chiellino, Antonella Ierardi, Rossana Ingargiola, Cirino Botta, Mariamena Arbitrio, Pierpaolo Correale, Pierfrancesco Tassone, Pierosandro Tagliaferri,